The DNA-editing technology developer has raised $10m in addition to the $65m it pulled in from investors including Leaps by Bayer in November.

US-based gene editing technology developer Metagenomi added $10m to a series A round featuring chemical and pharmaceutical producer Bayer yesterday, increasing it to $75m. Investment manager RA Capital Management put up the extra cash and is co-leading the round with Bayer subsidiary Leaps by Bayer and venture capital fund Humboldt Fund. The November 2020 first…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.